Zura Bio (ZURA) Competitors $4.42 +0.08 (+1.75%) As of 12:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZURA vs. SPRY, SYRE, UPB, CRON, NBTX, VALN, PGEN, RLAY, MNMD, and DNAShould you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include ARS Pharmaceuticals (SPRY), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Cronos Group (CRON), Nanobiotix (NBTX), Valneva (VALN), Precigen (PGEN), Relay Therapeutics (RLAY), Mind Medicine (MindMed) (MNMD), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Zura Bio vs. Its Competitors ARS Pharmaceuticals Spyre Therapeutics Upstream Bio Cronos Group Nanobiotix Valneva Precigen Relay Therapeutics Mind Medicine (MindMed) Ginkgo Bioworks Zura Bio (NASDAQ:ZURA) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer ZURA or SPRY? In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 1 mentions for Zura Bio. ARS Pharmaceuticals' average media sentiment score of 0.01 beat Zura Bio's score of -0.12 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ZURA or SPRY? Zura Bio presently has a consensus target price of $11.60, indicating a potential upside of 162.68%. ARS Pharmaceuticals has a consensus target price of $33.80, indicating a potential upside of 192.06%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Zura Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75ARS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has better valuation & earnings, ZURA or SPRY? ARS Pharmaceuticals has higher revenue and earnings than Zura Bio. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$45.39M-$0.70-6.31ARS Pharmaceuticals$112.34M10.18$8M-$0.49-23.62 Is ZURA or SPRY more profitable? Zura Bio has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -42.74%. ARS Pharmaceuticals' return on equity of -21.85% beat Zura Bio's return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -49.11% -40.06% ARS Pharmaceuticals -42.74%-21.85%-15.88% Which has more risk and volatility, ZURA or SPRY? Zura Bio has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Do institutionals and insiders believe in ZURA or SPRY? 61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryARS Pharmaceuticals beats Zura Bio on 12 of the 14 factors compared between the two stocks. Get Zura Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZURA vs. The Competition Export to ExcelMetricZura BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$288.04M$12.30B$9.08B$10.59BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-6.3321.9486.0127.55Price / SalesN/A275.28539.22204.66Price / CashN/A47.1237.9261.55Price / Book1.9510.2912.946.77Net Income-$45.39M-$52.40M$3.30B$275.88M7 Day Performance7.71%6.47%4.86%2.79%1 Month Performance100.73%16.21%10.02%9.25%1 Year Performance10.95%32.95%84.11%35.91% Zura Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZURAZura Bio2.9315 of 5 stars$4.42+1.8%$11.60+162.7%+3.1%$288.04MN/A-6.333SPRYARS Pharmaceuticals2.9156 of 5 stars$10.27-0.4%$33.17+222.9%-20.0%$1.02B$89.15M-20.9690Analyst ForecastSYRESpyre Therapeutics3.2771 of 5 stars$16.67+4.9%$54.29+225.6%-36.6%$1.01BN/A-4.9073Analyst DowngradeUPBUpstream Bio1.888 of 5 stars$18.97+1.8%$56.50+197.8%N/A$1.00B$2.37M0.0038Analyst ForecastCRONCronos Group1.0961 of 5 stars$2.55-1.2%N/A+23.5%$987.86M$130.28M51.00450Analyst ForecastNBTXNanobiotix1.2778 of 5 stars$22.78+11.1%$11.00-51.7%+423.2%$983.31M$39.18M0.00100Analyst ForecastAnalyst RevisionGap DownVALNValneva2.4566 of 5 stars$11.02-3.2%$15.00+36.1%+88.9%$978.71M$183.52M-11.24700Analyst ForecastGap UpPGENPrecigen4.4233 of 5 stars$3.14-3.4%$8.25+162.7%+276.3%$968.41M$3.92M-7.48190Analyst ForecastGap UpRLAYRelay Therapeutics2.8269 of 5 stars$5.59+2.0%$16.50+195.2%-2.2%$963.78M$8.36M-2.87330Positive NewsMNMDMind Medicine (MindMed)2.2731 of 5 stars$12.22-2.7%$26.50+116.9%+142.6%$955.66MN/A-7.9940Analyst ForecastGap UpDNAGinkgo Bioworks1.5306 of 5 stars$14.87-7.9%$9.00-39.5%+92.9%$955.48M$227.04M-2.54640News CoverageAnalyst Forecast Related Companies and Tools Related Companies SPRY Alternatives SYRE Alternatives UPB Alternatives CRON Alternatives NBTX Alternatives VALN Alternatives PGEN Alternatives RLAY Alternatives MNMD Alternatives DNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZURA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
